Abstract:Importance Colorectal cancer (CRC) is the third most common cause of cancer mortality worldwide with more than 1.85 million cases and 850 000 deaths annually. Of new colorectal cancer diagnoses, 20% of patients have metastatic disease at presentation and another 25% who present with localized disease will later develop metastases. Observations Colorectal cancer is the third most common cause of cancer mortality for men and women in the United States, with 53 200 deaths projected in 2020. Among people diagnosed with metastatic colorectal cancer, approximately 70% to 75% of patients survive beyond 1 year, 30% to 35% beyond 3 years, and fewer than 20% beyond 5 years from diagnosis. The primary treatment for unresectable metastatic CRC is systemic therapy (cytotoxic chemotherapy, biologic therapy such as antibodies to cellular growth factors, immunotherapy, and their combinations.) Clinical trials completed in the past 5 years have demonstrated that tailoring treatment to the molecular and pathologic features of the tumor improves overall survival. Genomic profiling to detect somatic variants is important because it identifies the treatments that may be effective. For the 50% of patients with metastatic CRC with KRAS/NRAS/BRAF wild-type tumors, cetuximab and panitumumab (monoclonal antibodies to the epithelial growth factor receptor [EGFR]), in combination with chemotherapy, can extend median survival by 2 to 4 months compared with chemotherapy alone. However, for the 35% to 40% of patients with KRAS or NRAS sequence variations (formerly termed mutations), effective targeted therapies are not yet available. For the 5% to 10% with BRAF V600E sequence variations, targeted combination therapy with BRAF and EGFR inhibitors extended overall survival to 9.3 months, compared to 5.9 months for those receiving standard chemotherapy. For the 5% with microsatellite instability (the presence of numerous insertions or deletions at repetitive DNA units) or mismatch repair deficiency, immunotherapy may be used in the first or subsequent line and has improved treatment outcomes with a median overall survival of 31.4 months in previously treated patients. Conclusions and Relevance Advances in molecular profiling of metastatic CRC facilitate the ability to direct treatments to the biologic features of the tumor for specific patient subsets. Although cures remain uncommon, more patients can anticipate extended survival. Genomic profiling allows treatment selection so that more patients derive benefit and fewer are exposed to toxicity from ineffective therapies.

The updates on metastatic mechanism and treatment of colorectal cancer

Mechanisms Regulating Colorectal Cancer Cell Metastasis into Liver (Review).

Delineating the Underlying Molecular Mechanisms and Key Genes Involved in Metastasis of Colorectal Cancer Via Bioinformatics Analysis

Molecular Network of Colorectal Cancer and Current Therapeutic Options

Colorectal liver metastasis: molecular mechanism and interventional therapy

Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches

Epithelial–mesenchymal transition in colorectal cancer metastasis: A system review

Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments

Advances in molecular biology and clinical practice of rectal liver metastases

Treatment progression in colorectal cancer liver metastasis

Mechanisms of metastatic colorectal cancer

Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements

Molecular Therapy of Colorectal Cancer: Progress and Future Directions

Current and potential treatment of colorectal cancer metastasis to bone

Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer

Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives

Current perspective on the treatment of advanced/metastatic colorectal cancer

Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review.

Biological factors driving colorectal cancer metastasis

Recent advances microRNAs and metabolic reprogramming in colorectal cancer research

Liver metastasis from colorectal cancer: pathogenetic development, immune landscape of the tumour microenvironment and therapeutic approaches